Summary
Global Markets Direct’s, ‘Gliosarcoma - Pipeline Review, H1 2016’, provides an overview of the Gliosarcoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Gliosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Gliosarcoma
- The report reviews pipeline therapeutics for Gliosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gliosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Gliosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gliosarcoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gliosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gliosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Amgen Inc.
Axelar AB
Burzynski Research Institute, Inc.
Celgene Corporation
ERC Belgium SA
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
NewLink Genetics Corporation
Novartis AG
Progenics Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Gliosarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Gliosarcoma - Overview 8
Pipeline Products for Gliosarcoma - Comparative Analysis 9
Gliosarcoma - Therapeutics under Development by Companies 10
Gliosarcoma - Therapeutics under Investigation by Universities/Institutes 11
Gliosarcoma - Pipeline Products Glance 12
Clinical Stage Products 12
Gliosarcoma - Products under Development by Companies 13
Gliosarcoma - Products under Investigation by Universities/Institutes 14
Gliosarcoma - Companies Involved in Therapeutics Development 15
Amgen Inc. 15
Axelar AB 16
Burzynski Research Institute, Inc. 17
Celgene Corporation 18
ERC Belgium SA 19
Merck & Co., Inc. 20
Millennium Pharmaceuticals, Inc. 21
NewLink Genetics Corporation 22
Novartis AG 23
Progenics Pharmaceuticals, Inc. 24
Gliosarcoma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
alisertib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Antineoplaston Therapy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AXL-1717 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CC-122 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DNX-2401 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ERC-1671 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
flucytosine + TBio-01 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
indoximod - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
irinotecan hydrochloride + TBio-02 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
lonafarnib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Oncolytic Virus to Target IL-12 for Oncology - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
p28 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
pazopanib hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PSMA ADC - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
rilotumumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Gliosarcoma - Recent Pipeline Updates 73
Gliosarcoma - Dormant Projects 88
Gliosarcoma - Product Development Milestones 89
Featured News & Press Releases 89
Nov 26, 2013: Burzynski Clinic Presents the Successful Treatment of a Child with Recurrent Diffuse Intrinsic Pontine Gliosarcoma at the Congress 89
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91
List of Tables
Number of Products under Development for Gliosarcoma, H1 2016 8
Number of Products under Development for Gliosarcoma - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Gliosarcoma - Pipeline by Amgen Inc., H1 2016 15
Gliosarcoma - Pipeline by Axelar AB, H1 2016 16
Gliosarcoma - Pipeline by Burzynski Research Institute, Inc., H1 2016 17
Gliosarcoma - Pipeline by Celgene Corporation, H1 2016 18
Gliosarcoma - Pipeline by ERC Belgium SA, H1 2016 19
Gliosarcoma - Pipeline by Merck & Co., Inc., H1 2016 20
Gliosarcoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 21
Gliosarcoma - Pipeline by NewLink Genetics Corporation, H1 2016 22
Gliosarcoma - Pipeline by Novartis AG, H1 2016 23
Gliosarcoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016 24
Assessment by Monotherapy Products, H1 2016 25
Assessment by Combination Products, H1 2016 26
Number of Products by Stage and Target, H1 2016 28
Number of Products by Stage and Mechanism of Action, H1 2016 30
Number of Products by Stage and Route of Administration, H1 2016 32
Number of Products by Stage and Molecule Type, H1 2016 34
Gliosarcoma Therapeutics - Recent Pipeline Updates, H1 2016 73
Gliosarcoma - Dormant Projects, H1 2016 88
List of Figures
Number of Products under Development for Gliosarcoma, H1 2016 8
Number of Products under Development for Gliosarcoma - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 12
Assessment by Monotherapy Products, H1 2016 25
Assessment by Combination Products, H1 2016 26
Number of Products by Top 10 Targets, H1 2016 27
Number of Products by Stage and Top 10 Targets, H1 2016 27
Number of Products by Top 10 Mechanism of Actions, H1 2016 29
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 29
Number of Products by Routes of Administration, H1 2016 31
Number of Products by Stage and Routes of Administration, H1 2016 31
Number of Products by Molecule Types, H1 2016 33
Number of Products by Stage and Molecule Types, H1 2016 33
